Answers are grounded in this paper and cite their sources.
Purpose: To assess the effectiveness of bevacizumab versus bevacizumab with macular laser photocoagulation in diabetic macular edema. Patients and Methods: Forty eyes of 31 patients with macular edema were enrolled in this study; Group A, twenty eyes received baseline three monthly injections of bevacizumab (1.25 mg/0.05 ml), then monthly reinjection according to pro re nata (PRN) regimen, and Group B, twenty eyes received one injection plus laser 1 month later, then monthly injections according to PRN regimen (? according to PRN also). Results: In Group A, no significant change in mean best-corrected visual acuity (BCVA) throughout 1 year (P = 0.165), as compared to Group B (P < 0.001). Mean BCVA in Group B at 12 months was 0.46 ± 0.30 compared with 0.75 ± 0.33 in Group A (P = 0.041).The mean number of injections in Group A was 5.55 times while in Group B was 1.4 times (P < 0.001). Conclusion: Combined treatment resulted in marked reduction of the number of injections required to control edema.
No takes yet. Share an insight, caveat, or question.
Alahmadawy et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: